KR930002511A - 인간 리노바이러스 수용체 단밸질의 다중형 - Google Patents

인간 리노바이러스 수용체 단밸질의 다중형 Download PDF

Info

Publication number
KR930002511A
KR930002511A KR1019910012433A KR910012433A KR930002511A KR 930002511 A KR930002511 A KR 930002511A KR 1019910012433 A KR1019910012433 A KR 1019910012433A KR 910012433 A KR910012433 A KR 910012433A KR 930002511 A KR930002511 A KR 930002511A
Authority
KR
South Korea
Prior art keywords
icam
group
multiple type
membrane
type
Prior art date
Application number
KR1019910012433A
Other languages
English (en)
Other versions
KR100208847B1 (ko
Inventor
엠. 그레브 제프리
맥클렌드 앨런
Original Assignee
원본미기재
몰레큘라 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 몰레큘라 테라퓨틱스 인크. filed Critical 원본미기재
Publication of KR930002511A publication Critical patent/KR930002511A/ko
Application granted granted Critical
Publication of KR100208847B1 publication Critical patent/KR100208847B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

내용 없음.

Description

인간 리노바이러스 수용체 단백질의 다중형
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (40)

  1. 다중형 ICAM.
  2. 제1항에 있어서, 상기 ICAM이 비-막투과 ICAM임을 특징으로 하는 다중형 ICAM.
  3. 제3항에 있어서, 상기 비-막투과 ICAM이 실제적으로 카르복실 세포간 도메인 및 소수성 막 도메인을 갖지 않음을 특징으로 하는 다중형 ICAM.
  4. 제2항에 있어서, 상기 비-막투과 ICAM이 tICAM(453) 및 tICAM(184)이 이루어진 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  5. 제1항에 있어서, 상기 ICAM이 지지체에 흡착됨으로써 다중화 됨을 특징으로 하는 다중형 ICAM.
  6. 제5항에 있어서, 상기 지지체가 불활성 중합체이며, 니트로 셀룰로오스, PVDF, DEAE, 지질 중합체 및 아미노 덱스트란으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  7. 제1항에 있어서, 상기 다중형 ICAM이 구성물질에 결합됨으로써 다중화됨을 특징으로 하는 다중형 ICAM.
  8. 제9항에 있어서, 상기 ICAM이 한쪽 말단에서 변형됨을 특징으로 하는 다중형 ICAM.
  9. 제8항에 있어서, 상기한 ICAM이 카르복실 말단에서 변형됨을 특징으로 하는 다중형 ICAM.
  10. 제8항에 있어서, 상기 ICAM이 반응성 아미노산 잔기를 포함하는 카르복실 말단에서 변형됨을 특징으로 하는 다중형 ICAM.
  11. 제10항에 있어서, 상기 반응성 아미노산이 리신 및 시스테인으로 이루어진 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  12. 제8항에 있어서, 상기 ICAM이 아미노 말단에서 변형됨을 특징으로 하는 다중형 ICAM.
  13. 제8항에 있어서, 상기 ICAM이 반응성 아미노산 잔기를 포함하는 아미노 말단에서 변형됨을 특징으로 하는 다중형 ICAM.
  14. 제13항에 있어서, 상기 반응성 아미노산이 리신 및 시스테인으로 이루어진 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  15. 제8항에 있어서, 상기 ICAM이 올리고머 마이셀의 형성을 증진시킬 수 있는 지질을 포함하는 한쪽 말단에서 변형됨을 특징으로 하는 다중형 ICAM.
  16. 제7항에 있어서, 상기 구성 물질이 항체, 단백질 담체 및 가교결합제로 이루어지는 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  17. 제16항에 있어서, 상기 항체가 항 ICAM항체 CL 203임을 특징으로 하는 다중형 ICAM.
  18. 제16항에 있어서, 상기 가교결합제가 헤테로2관능성 및 호모2관능성 가교결합제로 이루어진 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  19. 제18항에 있어서, 상기 가교결합제가 2관능성 N-히드록시 숙신이미드에스테르, 이미도에스테르 및 비스-말레이미도-헥산으로 이루어진 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  20. 제7항에 있어서, 상기 단백질 담체가 알부민 및 프로테오글리칸으로 이루어진 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  21. 제1항에 있어서, 상기 ICAM이 완전 글리코실화된 ICAM, 부분 글리코실화된 ICAM 또는 비-글리코실화된 ICAM으로 이루어진 군으로부터 선택된 것임을 특징으로 하는 다중형 ICAM.
  22. 리간드에 대한 비-막투과 ICAM의 결합이 증진된느 리간드에 대한 형태 및 구조로 비-막투과 ICAM을 존재시키는 단계로 이루어지는, 리간드에 대한 비-막투과 ICAM의 결합 증진 방법.
  23. 제22항에 있어서, 상기 비-막투과 ICAM이 실질적으로 카르복실 세포내 도메인 및 소수성 막 도메인을 갖지 않는 ICAM임을 특징으로 하는 방법.
  24. 제23항에 있어서, 상기 비-막투과 ICAM이 tICAM(453) 및 tICAM(184)로 이루어진 군으로부터 선택된 것임을 특징으로 하는 방법.
  25. 제22항에 있어서, 상기 ICAM이 다중형 구조임을 특징으로 하는 방법.
  26. 제22항에 있어서, 상기 ICAM이 카르복실 말단 또는 아미노 말단에서 변형되고 다중형 ICAM형성이 증진됨을 특징으로 하는 방법.
  27. 제26항에 있어서, 상기 변형이 카르복실 말단에서 리신의 첨가로 이루어짐을 특징으로 하는 방법.
  28. 제26항에 있어서, 상기 변형이 카르복실 말단에서 유리 시스테인의 첨가로 이루어짐을 특징으로 하는 방법.
  29. 제25항에 있어서, 상기 다중형 구조가 다이머 구조임을 특징으로 하는 방법.
  30. 제25항에 있어서, 상기 다중형 구조가 제2ICAM에 가교결합되 제1ICAM임을 특징으로 하는 방법.
  31. 제25항에 있어서, 상기 다중형 구조가 다중형 구조를 형성하는 지지체에 흡착된 ICAM임을 특징으로 하는 방법.
  32. 제31항에 있어서, 상기 지지체가 고분자량이고 실질적으로 불활성인 중합체로 이루어지는 군으로부터 선택된 것임을 특징으로 하는 방법.
  33. 제32항에 있어서, 상기 중합체가 불활성 중합체이고 니트로 셀룰로오스, PVDF, DEAE, 지질 중합체 및 아미노 덱스트란으로 이루어지는 군으로부터 선택된 것임을 특징으로 하는 방법.
  34. 제32항에 있어서, 상기 다중형 ICAM이 구성물질에 결합됨으로써 다중화됨을 특징으로 하는 방법.
  35. 제34항에 있어서, 상기 구성물질이 항체, 단백질 담체 및 가교결합제로 이루어지는 군으로부터 선택된 것임을 특징으로 하는 방법.
  36. 제35항에 있어서, 상기 가교결합제가 헤테로2관능성 및 호모2관능성 가교결합제로 이루어지는 군으로부터 선택된 것임을 특징으로 하는 방법.
  37. 제32항에 있어서, 상기 단백질 담체가 알부민 및 프로테오글리칸으로 이루어지는 군으로부터 선택된 것임을 특징으로 하는 방법.
  38. 제37항에 있어서, 상기 항체가 항 ICAM항체 CL203임을 특징으로 하는 방법.
  39. 제22항에 있어서, 상기 리간드가 인간 리노바이러스, 주요 군 수용체 바이러스, 임파구 관련 항체-1(LFA-1) 및 플라스모디움 팔시파륨으로 이루어진 군으로부터 선택된 것임을 특징으로 하는 방법.
  40. 제약학상 허용 가능한 용매, 희석제, 보조제 또는 담체 및 유효 성분으로서 제1하에 따른 폴리펩티디 유효량으로 이루어지는 제약 조성물.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019910012433A 1990-07-20 1991-07-20 인간 리노바이러스 수용체 단백질의 다중형 KR100208847B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55623890A 1990-07-20 1990-07-20
US556,238 1990-07-20

Publications (2)

Publication Number Publication Date
KR930002511A true KR930002511A (ko) 1993-02-23
KR100208847B1 KR100208847B1 (ko) 1999-07-15

Family

ID=24220489

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910012433A KR100208847B1 (ko) 1990-07-20 1991-07-20 인간 리노바이러스 수용체 단백질의 다중형

Country Status (14)

Country Link
US (1) US6096862A (ko)
EP (2) EP0987329A3 (ko)
JP (1) JP3091527B2 (ko)
KR (1) KR100208847B1 (ko)
AT (1) ATE184049T1 (ko)
DE (1) DE69131564T2 (ko)
DK (1) DK0468257T3 (ko)
ES (1) ES2134762T3 (ko)
FI (1) FI105687B (ko)
GR (1) GR3031768T3 (ko)
IE (1) IE912552A1 (ko)
IL (1) IL98866A0 (ko)
PT (1) PT98394B (ko)
ZA (1) ZA915678B (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
JP3616090B2 (ja) * 1992-01-27 2005-02-02 イコス コーポレイション 細胞間接着分子関連タンパク質
US5773218A (en) * 1992-01-27 1998-06-30 Icos Corporation Method to identify compounds which modulate ICAM-related protein interactions
US5753502A (en) * 1993-08-05 1998-05-19 Icos Corporation Neuron-specific ICAM-4 promoter
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5852170A (en) * 1992-01-27 1998-12-22 Icos Corporation ICAM-4 materials and methods
US5700658A (en) * 1992-01-27 1997-12-23 Icos Corporation ICAM-4 materials and methods
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US5773293A (en) * 1992-01-27 1998-06-30 Icos Corporation Anti-ICAM-4 antibodies and hybridomas
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5702917A (en) * 1992-01-27 1997-12-30 Icos Corporation Polynucleotides encoding human ICAM-4
JPH06510208A (ja) * 1992-06-22 1994-11-17 マイルス・インコーポレーテツド 多量体形態のヒトライノウイルスレセプタ蛋白質
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US20020168367A1 (en) 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
ATE442386T1 (de) * 2000-04-28 2009-09-15 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
EP2007401A2 (en) * 2006-04-04 2008-12-31 Marinomed Biotechnologie GmbH Anti-inflammatory polymer
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261928A (en) * 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4209526A (en) * 1977-08-05 1980-06-24 Sterling Drug Inc. Antiviral arylenedioxyalkyl substituted pyrazoles
US4171365A (en) * 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
JPS551594A (en) * 1978-06-12 1980-01-08 Corning Glass Works Measuring antigen receptor on cell membrane
US4232161A (en) * 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4234725A (en) * 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4427653A (en) * 1981-01-26 1984-01-24 President And Fellows Of Harvard College Method of making monoclonal antibodies
US4372976A (en) * 1981-08-07 1983-02-08 Sterling Drug Inc. Novel aryl-aliphatic ketone and its use as an antiviral agent
US4451476A (en) * 1982-12-13 1984-05-29 Sterling Drug Inc. Isoxazoles as antiviral agents
CA1299176C (en) * 1985-07-02 1992-04-21 Guy Dominic Diana Process for preparing isoxazole and furan derivatives
US4843087A (en) * 1983-08-29 1989-06-27 Sterling Drug Inc. Di-heterocyclic compounds and their use as antiviral agents
EP0169146A3 (en) * 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
EP0169729A3 (en) * 1984-07-23 1988-08-03 Becton Dickinson and Company Recovery of cell receptors
DE3505148A1 (de) * 1985-02-15 1986-10-30 Boehringer Ingelheim International GmbH, 6507 Ingelheim Polypeptide des rhinovirusstammes hrv2 sowie die hierfuer codierenden dna-molekuele
EP0227604A3 (en) * 1985-12-23 1989-01-18 Sandoz Ag Use of oligopeptides in the treatment of viral infections
EP0261403A3 (de) * 1986-08-23 1988-04-13 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
ATE98649T1 (de) * 1987-02-26 1994-01-15 Dana Farber Cancer Inst Inc Reinigung von lfa-3.
EP0303692A4 (en) * 1987-02-26 1990-12-05 Dana Farber Cancer Institute Cloning of lfa-1
US5304636A (en) * 1987-04-14 1994-04-19 Boehringer Ingelheim International Gmbh Receptor for the human rhinovirus minor group
US5603932A (en) * 1987-04-14 1997-02-18 Boehringer Ingelheim International Gmbh Receptor of the minor human rhinovirus receptor group
DE3712678A1 (de) * 1987-04-14 1988-10-27 Boehringer Ingelheim Int Rezeptor der kleinen rhinovirus rezeptor gruppe
US5831036A (en) * 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
EP0289949B1 (en) * 1987-05-04 1995-10-04 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
AU629189B2 (en) * 1987-05-04 1992-10-01 Dana-Farber Cancer Institute Intercellular adhesion molecules and their binding ligands
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
WO1989010938A1 (en) * 1988-05-04 1989-11-16 Dana-Farber Cancer Institute Protein micelles
DE68923048T2 (de) * 1988-08-23 1995-11-16 Dana Farber Cancer Inst Inc Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
EP0364690A3 (en) * 1988-08-23 1990-07-18 Dana Farber Cancer Institute The alpha-subunit of the mac-1 leukocyte adhesion receptor
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
ES2141076T3 (es) * 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
ATE125708T1 (de) * 1988-09-28 1995-08-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
ATE146222T1 (de) * 1989-03-09 1996-12-15 Blood Res Center Interzellulares adhäsions-molekül-2 und seine bindungsliganden
DK0387701T3 (da) * 1989-03-09 1992-12-07 Boehringer Ingelheim Pharma Anvendelse af intercellulære adhæsionsmolekyler samt deres bindende ligander ved behandling af astma
DE69033983T2 (de) * 1989-03-16 2003-03-20 Blood Res Center Verwendung von funktionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
HU217792B (hu) * 1989-03-16 2000-04-28 Dana Farber Cancer Institute Eljárás intercelluláris adhéziós molekula (ICAM-1) oldható származékai és ezeket tartalmazó gyógyszerkészítmények előállítására
US5324510A (en) * 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0459577A3 (en) * 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
JPH06500555A (ja) * 1990-08-27 1994-01-20 カイロン　コーポレイション 病気の処置のためのペプチドの薬物
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
CA2074825C (en) * 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
EP0510483A1 (en) * 1991-04-22 1992-10-28 Boehringer Ingelheim Pharmaceuticals Inc. Method for the detection of viruses
US5223396A (en) * 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
CA2120506C (en) * 1991-10-04 2000-12-12 Scott M. Whitcup Treatment of ocular inflammation by blockage of cell adhesion molecules
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
JP3616090B2 (ja) * 1992-01-27 2005-02-02 イコス コーポレイション 細胞間接着分子関連タンパク質
CA2092645A1 (en) * 1992-03-13 1993-09-14 Maureen K. Highkin Production of recombinant proteins using herpes virus promoters and vp16 transactivators
US5580969A (en) * 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA

Also Published As

Publication number Publication date
JP3091527B2 (ja) 2000-09-25
EP0468257B1 (en) 1999-09-01
EP0987329A2 (en) 2000-03-22
KR100208847B1 (ko) 1999-07-15
IL98866A0 (en) 1992-07-15
EP0468257A1 (en) 1992-01-29
DE69131564T2 (de) 2000-01-13
DE69131564D1 (de) 1999-10-07
ATE184049T1 (de) 1999-09-15
AU8117691A (en) 1992-01-23
AU652567B2 (en) 1994-09-01
PT98394A (pt) 1992-06-30
DK0468257T3 (da) 2000-03-27
EP0987329A3 (en) 2004-03-03
GR3031768T3 (en) 2000-02-29
US6096862A (en) 2000-08-01
FI913470A (fi) 1992-01-21
ES2134762T3 (es) 1999-10-16
FI105687B (fi) 2000-09-29
JPH04297499A (ja) 1992-10-21
PT98394B (pt) 1999-01-29
IE912552A1 (en) 1992-01-29
ZA915678B (en) 1992-05-27
FI913470A0 (fi) 1991-07-18

Similar Documents

Publication Publication Date Title
KR930002511A (ko) 인간 리노바이러스 수용체 단밸질의 다중형
Rajagopalan et al. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity
Sakihama et al. Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120.
Lew et al. Characterization of T cell receptor gamma chain expression in a subset of murine thymocytes
Spits et al. Characteristics of a monoclonal antibody (WT-31) that recognizes a common epitope on the human T cell receptor for antigen.
US5695760A (en) Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US6117656A (en) Cloned genes encoding IG-CD4 fusion proteins and the use thereof
JP2001506609A (ja) 生理活性の増加した多量体エリスロポエチン
JP2002511424A5 (ko)
Lynch et al. Direct evidence for native CD4 oligomers in lymphoid and monocytoid cells
KR920018079A (ko) 폴리에틸렌 단백질 결합체
Goudemand et al. Acquired type II von Willebrand's disease: demonstration of a complexed inhibitor of the von Willebrand factor‐platelet interaction and response to treatment
Coppens et al. A rapid method purifies a glycoprotein of Mr 145,000 as the LDL receptor of Trypanosoma brucei brucei
Jin et al. A fraction of CD3 epsilon subunits exists as disulfide-linked dimers in both human and murine T lymphocytes.
CA1338079C (en) Adhesion protein micelles
Schafer et al. The assembly and stability of MHC class II-(αβ) 2 superdimers
AU675441B2 (en) Multimeric forms of human rhinovirus receptor protein
Kuijpers et al. Analysis of the role of leukocyte function-associated antigen-1 in activation of human influenza virus-specific T cell clones.
Bjerke et al. Fc gamma-receptors and HLA-DR antigens on endothelial cells in psoriatic skin lesions
Chandler et al. CD4-binding compounds: An assay to detect new classes of immunopharmacological agents
RU2126449C1 (ru) Производное вещества межклеточной адгезии icam-1, последовательность днк
Allgren BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF SOLUBILIZED S (, 1) SEROTONIN BINDING PROTEINS FROM MAMMALIAN BRAIN.
CA2068651A1 (en) Production of multimeric glycoproteins through chemical coupling
Krensky et al. Human lymphocyte function associated antigens
Sauve Hepatic protein synthesis during the asymptomatic phase of methylmercury poisoning in the rat.

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110407

Year of fee payment: 13

EXPY Expiration of term